NEW YORK, Feb. 9 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Kinase Therapeutics: Pipeline Assessment and Commercial Prospects - Overview

http://www.reportlinker.com/p0176024/Kinase-Therapeutics-Pipeline-Assessment-and-Commercial-Prospects---Overview.html

The number of kinase inhibitors entering clinical development has increased significantly in recent years. In addition to major pharmaceutical and biotech companies, an increasing number of emerging companies are focusing on their development. By 2020, small-molecule kinase inhibitors could generate annual revenues > $25 billion. This report assesses:

• R&D considerations specific to targeting kinases
• Current kinase inhibitor pipelines
• Commercial successes to date
• Near- and longer-term market outlook
• Corporate activities of firms involved with kinases

Kinases are now firmly established as a major class of drug targets. It was previously thought that kinases would be intractable drug targets due to the presumed need to compete with ATP and the assumption that sufficient selectivity would be unattainable. However, considerable progress has been made in understanding kinases and their function, and the past few years have seen a number of kinase inhibitors reach the market. Imatinib (Novartis' Gleevec) is currently the most commercially successful, with sales reaching $3.7 billion in 2008. Erlotinib (OSI/Roche's Tarceva) generated revenues of $1.1 billion the same year.

In recent years, there has been an explosion in the number of kinase inhibitors entering the clinic, and many more are in preclinical development. Kinase Therapeutics: Pipeline Assessment and Commercial Prospects identifies which kinase families and their respective members have attracted the greatest interest for therapeutic development and in which indications these kinases play a physiological or pathophysiological role and thus are most relevant for kinase inhibitor development. 

CHAPTER 1

KINASES

1.1. The Function of Kinases

1.2. The Human Kinome

1.3. Kinase Classification

AGC Family

CAMK Family

CMGC Family

CK1 Family

STE Family

TK Family

TKL Family

Atypical Protein Kinases

1.4. Kinase Structure

1.5. Kinases as Drug Targets

CHAPTER 2

INDICATIONS

2.1. Introduction

2.2. Cancer

2.3. Angiogenic Conditions

2.4. Inflammatory Diseases

2.5. Metabolic Disorders

2.6. CNS Conditions

2.7. Cardiovascular Disease

CHAPTER 3

R&D CONSIDERATIONS

3.1. Introduction

3.2. Kinase Selectivity

Profiling

Selectivity Profiles of Selected Inhibitors

How Selective?

3.3. Structural Features

X-Ray Structures and Multiple Conformations

3.4. Kinase Mutations

Bcr-Abl

Pharmacogenomics

3.5. Intellectual Property Issues

CHAPTER 4

CURRENT COMMERCIAL SUCCESSES

4.1. Introduction

4.2. Small Molecules

Overview

Abl Inhibitors

Gleevec (imatinib)

Tasigna (nilotinib) and Sprycel (dasatinib)

EGF Family Inhibitors

Tarceva (erlotinib) and Iressa (gefitinib)

Tykerb (lapatinib)

Multi-Kinase Inhibitors

Nexavar (sorafenib)

Sutent (sunitinib)

Palladia (toceranib) and Masivet (mastinib)

mTOR Inhibitors

Rapamune (sirolimus)

Torisel (temsirolimus), Afinitor/Certican (everolimus), Endeavor (zotarolimus)

Rho Inhibitor

Eril (fasudil)

4.3. Biological Agents

CHAPTER 5

CURRENT KINASE INHIBITOR PIPELINES

5.1. Introduction

5.2. Overview

5.3. Kinase Inhibitors in Phase III

Enzastaurin and Ruboxistaurin

Midostaurin

Pan-VEGFR Inhibitors

Votrient (pazopanib)

Cediranib

Motesanib

Axitinib

Aflibercept

Vandetanib

BIBW-2992

Neratinib

Pertuzumab

FGFR Inhibitors

BIBF-1120

Brivanib

Alvocidib

Bosutinib

Lestaurtinib

Ridaforolimus

Masitinib

BMS-907351

CP-690550

INCB-18424

5.4. Kinase Inhibitors in Phase II Development

5.5. Kinase Inhibitors in Phase I Development

5.6. Growth Factor Receptor Kinases

ErbB Family Kinases

ErbB2 and ErbB3

ErbB2 and EGFR

Pan-ErbB

Antibodies

FGF

IGF

VEGF

Multi-Kinase Inhibitors

Flt3

5.7. Popular Kinase Cascades

PI3K, Akt, mTOR, S6K

Perifosine

Triciribine

Archexin

Ras, Raf, MEK, ERK

Roche

Ardea Biosciences and Bayer

Array and AstraZeneca

JAK Family

5.8. Cell Cycle Inhibitors

Cyclic-Dependent Kinase (CDK)

Checkpoint Kinase (Chk)

Polo-Like Kinase (PLK)

BI-2536 and BI-6727

5.9. Popular Kinase Targets

Abl

p38

GSK-3

Protein Kinase C

Aurora

Broad Spectrum

Pan-Aurora

Aurora 1

Aurora 2

c-Met

Rho

JNK

Src Family

Kinases in Inflammatory Diseases

5.10. Other Kinases

Serine/Threonine Kinases

Tyrosine Kinases

Tyrosine-Like, CAMK, and Atypical Kinases

5.11. Outlook

CHAPTER 6

CORPORATE ACTIVITIES

6.1. Introduction

6.2. Major Companies

Abbott

Amgen

Astellas

AstraZeneca

Bayer

Boehringer Ingelheim

Bristol-Myers Squibb

Daiichi Sankyo

Eisai

Eli Lilly

GlaxoSmithKline

Johnson & Johnson

Merck & Co.

Merck Serono

Novartis

Pfizer

Roche

sanofi-aventis

Takeda

6.3. Specialist Companies

ACT Biotech

Advenchen

Array BioPharma

Avila Therapeutics

Calistoga Pharmaceuticals

Cellzome

Cyclacel Pharmaceuticals

Cylene Pharmaceuticals

Deciphera Pharmaceuticals

Emiliem

Exelixis

Intellikine

Kai Pharmaceuticals

Nerviano Medical Sciences

Oncalis

OSI Pharmaceuticals

Rigel Pharmaceuticals

S*Bio

Semafore Pharmaceuticals

SuperGen

TargeGen

Vertex Pharmaceuticals

6.4. Service Companies

Ambit Biosciences

Galapagos

Invitrogen

KINAXO Biotechnologies

ProQinase

SignalChem

Upstate (Millipore)

CHAPTER 7

MARKET OUTLOOK

7.1. Introduction

7.2. Near-Term Developments

7.3. Longer-Term Outlook

CHAPTER 8

EXPERT INTERVIEWS

REFERENCES

COMPANY INDEX WITH WEB ADDRESSES

To order this report:

Pharmaceutical Industry: Kinase Therapeutics: Pipeline Assessment and Commercial Prospects - Overview

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

Back to top

RELATED LINKS
http://www.reportlinker.com